Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene

Gene Therapy

Volumn 5, Issue 6, 1998, Pages 761-769

  Bai, H ^a   Morishita, R ^a,d   Kida, I ^a   Yamakawa, T ^a   Zhang, W ^a   Aoki, M ^a   Matsushita, H ^a   Noda, A ^b   Nagai, R ^c   Kaneda, Y ^a   Higaki, J ^a   Ogihara, T ^a   Sawa, Y ^a   Matsuda, H ^a,d  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b KOBE UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Cell cycle regulatory gene; Gene therapy; Phenotype; Remodelling; Venous arterial graft failure

Indexed keywords

PROTEIN P21; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL AGING; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE TRANSFER; IMMUNOHISTOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RABBIT; SENESCENCE; TUMOR SUPPRESSOR GENE; VASCULAR SMOOTH MUSCLE; VEIN GRAFT;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 7344222019     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300640     Document Type: Article

References (49)

1. Holzenbein TJ et al. Results of a policy with arm veins used as the first alternative to an unavailable ipsilateral greater saphenous vein for infrainguinal bypass. J Vasc Surg 1996; 23: 130-140.
2. Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia a review. J Vasc Surg 1991; 13: 885-891.
3. Grondin CM et al. Coronary artery bypass grafting with saphenous vein. Circulation 1989; 79: 124-129.
4. Angelini GD, Newby AC. The future of saphenous vein as a coronary artery bypass conduit. Eur Heart J 1989; 10: 273-280.
5. Cox JL, Chaisson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991; 34: 45-68.
6. Galbut DL et al. Seventeen-year expenence with bilateral internal mammary artery grafts. Ann Thorac Surg 1990; 49: 195-201.
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
8. Holt CM et al. Comparison of response to injury in organ culture of human saphenous vein and internal mammary artery. Ann Thorac Surg 1993; 55: 1522-1528.
9. Angelini GD et al. Time-course of medial and intimal thickening in pig venous arterial grafts: relationship to endothelial injury and cholesterol accumulation. J Thorac Cardiovasc Surg 1992; 103: 1093-1102.
10. Libby P et al. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation 1992; 86: III-47-III-52.
11. Clowes AW, Clowes MM, Fingerle J, Reidy MA. Regulation of smooth muscle cell growth in injured artery. J Cardiovasc Pharmacol 1989; 14: S12-S15.
12. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991; 88: 3739-3743.
13. Ferns GAA et al. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253: 1129-1132.
14. Majesky MW et al Production of transforming growth factor beta-1 during repair of artenal injury. J Clin Invest 1991; 88: 904-910.
15. Pagano M et al. Cyclin A is required at two points in the human cell cycle. EMBO J 1992; 11: 961-971.
16. Pardee AB A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci USA 1974; 71: 1286-1290.
17. Weintraub SJ, Prater CA, Dean DC. Retinoblastoma protein switches the E2F site from positive to negative element. Nature 1992; 358: 259-261.
18. Pagano M, Draetta G, Durr J. Association of cdk 2 kinase with the transcription factor E2F during S phase. Science 1992; 255: 1144-1147.
19. Morishita R et al. Single intraluminal delivery of antisense cdc 2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474-8478.
20. Morishita R et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest 1994; 93: 1458-1464.
21. Vogelstein B, Kinzler KW. P53 function and dysfunction. Cell 1992; 70: 523-526.
22. Lane DP. p53, Guardian of the genome. Nature 1992; 258: 15-16.
23. Noda A et al. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211: 90-98.
24. El-Deiry WS et al. WAF 1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
25. Harper JW et al. The p21 CDK-interacting protein Cip 1 is a potential inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
26. Mann MJ et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA 1995; 92: 4502-4506.
27. Chang MW et al. Adenovirus-mediated overexpression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995; 96: 2260-2268.
28. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-578.
29. Matsumoto T et al. Hemagglutinating virus of Japan-liposome mediated gene transfer of endothelial cell nitric oxide synthase inhibits intimal hyperplasia of canine vein grafts under conditions of poor runoff. J Vasc Surg 1998; 271: 125-144.
30. Morishita R et al. Novel in vitro gene transfer method for study of local modulators in vascular smooth muscle cells. Hypertension 1993; 21: 894-899.
31. Leyen HVL et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of ec-nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92: 1137-1141.
32. Yonemitsu Y et al. Characterization of in vivo gene transfer into the arterial wall mediated by the Sendai virus (hemagglutinating virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. Lab Invest 1996; 75: 313-323.
33. Nagai R, Kuro-o M, Babij P, Periasamy M. Identification of two types of smooth muscle myosin heavy chain isoforms by cDNA cloning and immunoblot analysis. J Biol Chem 1989; 264: 9734-9737.
34. Kuro-o M et al. cDNA cloning of a myosin heavy chain isoform in embryonic smooth muscle and its expression during vascular development and in arteriosclerosis. J Biol Chem 1991; 266: 3768-3773.
35. Kim HS et al. Ductus arteriosus. Advanced differentiation of smooth muscle cells demonstrated by myosin heavy chain isoform expression in rabbits. Circulation 1993; 88: 1804-1810.
36. Okamoto E et al. Heterogeneity in smooth muscle cell population accumulating in the neointima and the media of poststenotic dilation of the rabbit carotid artery. Biochem Biophys Res Commun 1992; 185: 459-464.
37. Medford RM, Nguyen HT, Nadal-Ginard B. Transcriptional and cell cycle-mediated regulation of myosin heavy chain gene expression during muscle cell differentiation. J Biol Chem 1983; 258: 11063-11073.
38. Kato S, Shanley JR, Fox JC. Serum stimulation, cell-cell interactions, and extracellular matrix independently influence smooth muscle cell phenotype in vitro. Am J Pathol 1996; 149: 687-697.
39. Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest 1990; 85: 731-738.
40. Majesky MW, Giachelli CM, Rediy MA, Schwartz SM. Rat carotid neointimal smooth muscle cells re-express a developmentally regulated mRNA phenotype during repair of arterial injury. Circ Res 1992; 71: 759-768.
41. Grainger DJ et al. Transforming growth factor beta decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase. Biochem J 1994; 299: 227-235.
42. Satterwhite LL et al. Phosphorylation of myosin-Il regulatory light chain by cyclin-p34cdc2: a mechanism for the timing of cytokinesis. J Cell Biol 1992; 118: 595-605.
43. McCollum D et al. Schizosaccharomyces pombe cdc4+ gene encodes a novel EF-hartd protein essential for cytokinesis. J Cell Biol 1995; 130: 651-660.
44. Takebe Y et al. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T cell leukemia virus type 1 long terminal repeat. Mol Cell Biol 1988; 8: 466-472.
45. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA comtroduced with nuclear protein in adult rat liver. Science 1989; 243: 375-378.
46. Morishita R et al. Evidence for direct local effect of angiotensin in vascular hypertrophy: in vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1994; 94: 978-984.
47. Okada Y. Sendai virus-induced cell fusion. In: Abelson JN, Simon MI (eds). Methods in Enzymology. Academic Press: San Diego, 1993, pp 18-41.
48. Mizuta T et al. Total no-microsuture technique for rat lung transplantation. J Thorac Cardiovasc Surg 1991; 102: 159-160.
49. Bai H et al. Neointima formation after vascular stent implantation. Spatial and chronological distribution of smooth muscle cell proliferation and phenotypic modulation. Arterioscler Thromb 1994; 14: 1846-1853.